Coronary Stents Market Report, published
by Allied Market Research, projects that the global market was valued at $4,806
million in 2015, and is projected to reach at $9,003 million by 2022, growing
at a CAGR of 9.5% from 2016 to 2022. The drug-eluting stents (DES) segment
accounted for nearly half of the total market in 2015.
Click Here
To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2187
Coronary stents are small elastic tubes used
for the treatment of narrowed and blocked coronary arteries in patients with
coronary artery disease (CAD). These reduce the symptoms of chest pain (angina)
and aid in the treatment of a heart attack. These types of stents are also
called as heart stents or cardiac stents. They comprise metal mesh and are
implanted in constricted coronary arteries during a technique known as
percutaneous coronary intervention (PCI) or angioplasty.
Factors that drive the growth of the global
coronary stents market are increase in prevalence of CAD, improved patient
outcomes with stenting, and emergence of new trends in the field of coronary
artery stents. In addition, increase in demand for coronary stents from the
emerging countries and growth in awareness about availability of suitable
insurance & reimbursement policies provide opportunities to the coronary
stents manufacturers. However, high cost of procedures associated with coronary
stents and availability of substitute method for the treatment of CAD are
expected to hamper the market growth.
DES is expected to maintain its dominant
position throughout the analysis period, owing to its significant property of
preventing the growth of scar tissue (restenosis) in the arterial wall after
the procedure. In addition, with the advancements in stents field, DES have
been significantly improved and show reduction in stent thrombosis. Moreover,
they provide improved outcomes for patients with CAD treated with percutaneous
coronary intervention (PCI).
The metallic biomaterials segment dominated
with three-fourths of the market, in 2015, owing to cost-effectiveness of these
materials. Metallic biomaterials provide efficacy of vascular healing as
compared to other materials. These are used to manufacture expandable and
drug-eluting stents. The global metallic biomaterials market segment is
expected to grow at a CAGR of 9.5%.
In 2015, Asia-Pacific and LAMEA collectively
accounted for one-fourth of the total coronary stents market and are expected
to continue this trend due to increase in stents development, specifically in
China, India, and the other developing countries. Rise in geriatric population
is the main reason for the growth of coronary stents market in the Asia-Pacific
region.
The major companies profiled in the report
include Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc.,
Medtronic plc., Microport Scientific Corporation, B. Braun Melsungen AG, Terumo
Corporation, Biotronik SE & Co. KG, Biosensors International Group, Ltd.,
and Stentys SA.
The other companies that are included in the
coronary stents market are Meril Life Sciences Pvt. Ltd., Vascular Concepts
Limited, Translumina GmbH, REVA Medical, Inc., and Elixir Medical Corporation.
For
Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2187
Key Findings of the Coronary
Stents Market Study:
- The bio-absorbable stents are anticipated
to grow at a highest rate during the analysis period from 2016 to 2022.
- Asia-Pacific is projected to maintain its
lead position throughout 2022, growing at a CAGR of 11.5%.
- The metallic biomaterial segment occupied
more than half of the total market in 2015.
- China occupied one-fourth of the share of
the total Asia-Pacific coronary stents market in 2015.
- India is expected to grow at the highest
CAGR of 14.2% from 2016 to 2022
No comments:
Post a Comment